Ekso Bionics (NASDAQ:EKSO) Shares to Reverse Split on Monday, June 2nd

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) shares are set to reverse split before the market opens on Monday, June 2nd. The 1-15 reverse split was announced on Monday, May 19th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, May 30th.

Ekso Bionics Trading Up 1.5%

Shares of NASDAQ:EKSO opened at $0.30 on Thursday. The business’s 50 day simple moving average is $5.87 and its 200 day simple moving average is $7.99. Ekso Bionics has a 1 year low of $0.23 and a 1 year high of $1.53. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.81 and a quick ratio of 2.14. The company has a market capitalization of $10.58 million, a P/E ratio of -0.46 and a beta of 1.09.

Ekso Bionics (NASDAQ:EKSO) last announced its quarterly earnings data on Monday, May 5th. The company reported ($1.80) earnings per share for the quarter, missing the consensus estimate of ($1.65) by ($0.15). The company had revenue of $3.38 million during the quarter, compared to analyst estimates of $4.62 million. Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. On average, research analysts anticipate that Ekso Bionics will post -0.48 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have commented on EKSO. Wall Street Zen assumed coverage on shares of Ekso Bionics in a report on Thursday, May 22nd. They issued a “hold” rating on the stock. HC Wainwright cut their target price on Ekso Bionics from $135.00 to $60.00 and set a “buy” rating for the company in a research note on Tuesday, May 6th. Finally, Lake Street Capital reduced their target price on Ekso Bionics from $30.00 to $15.00 and set a “buy” rating on the stock in a report on Tuesday, March 4th.

Institutional Investors Weigh In On Ekso Bionics

A hedge fund recently raised its stake in Ekso Bionics stock. Armistice Capital LLC raised its stake in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 18.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,042,382 shares of the company’s stock after buying an additional 316,733 shares during the period. Armistice Capital LLC owned 7.03% of Ekso Bionics worth $823,000 at the end of the most recent quarter. 6.42% of the stock is currently owned by institutional investors.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.